Status:
UNKNOWN
Increase in Response by Offering Self-sampling Devices in Belgian GP Practices to Non-screened Women
Lead Sponsor:
Sciensano
Collaborating Sponsors:
Horizon 2020 - European Commission
Conditions:
Cervical Cancer
Eligibility:
FEMALE
30-64 years
Phase:
NA
Brief Summary
Small scale data indicate that cervical cancer screening participation may increase when self-sampling (SS) devices are offered directly by health care workers to non-screened woman, when those woman ...
Detailed Description
Screening with clinically validated high-risk (hr) HPV tests is more effective in reducing cervical cancer incidence than cytology. Another advantage of hrHPV testing is that it can be performed on se...
Eligibility Criteria
Inclusion
- women who have not been screened for cervical cancer since the last three years
- visiting their GP for whatever reason
Exclusion
- pregnant women,
- women under active follow-up because of previous cervical abnormality,
- women who had a total hysterectomy,
- women who had a history of cervical cancer or a treatment for cervical precancer less than three years ago,
- non-consenting women,
- women who are not able to understand and sign the informed consent
Key Trial Info
Start Date :
April 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04903561
Start Date
April 19 2021
End Date
June 1 2024
Last Update
November 24 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Université catholique de Louvain
Brussels, Belgium, 1080
2
Université de Liège
Liège, Belgium, 4000
3
Maison médicale Neptune
Schaarbeek, Belgium, 1030